Vaginitis Therapeutics Market Size, Share, & Trends Analysis Report By Product (Anti-fungal, Hormone, Anti-bacterial), By Type (OTC, Prescription), By Region (APAC, MEA, North America), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing prevalence of vaginitis
3.1.1.2 Rising R & D activities for vaginitis therapeutics
3.1.1.3 Changing lifestyle pattern of women
3.1.2 Market restraint analysis
3.1.2.1 Availability of alternative or natural remedies
3.2 Vaginitis Therapeutics - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.3 Industry Analysis - Porter’s
Chapter 4 Market Categorization 1: Product Estimates & Trend Analysis
4.1 Vaginitis Therapeutics Market: Product Movement Analysis
4.2 Anti-fungal
4.2.1 Anti-fungal market, 2014 - 2025 (USD Million)
4.3 Anti-bacterial
4.3.1 Anti-bacterial, 2014 - 2025 (USD Million)
4.4 Hormone
4.4.1 Hormone market, 2014 - 2025 (USD Million)
Chapter 5 Market Categorization 2: Type Estimates & Trend Analysis
5.1 Vaginitis Therapeutics Market: Type Movement Analysis
5.2 Over the counter (OTC)
5.2.1 Over the counter (OTC) market, 2014 - 2025 (USD Million)
5.3 Prescription (Rx)
5.3.1 Prescription (Rx), 2014 - 2025 (USD Million)
第六章市场分类3:区域大霸王tes & Trend Analysis, by Product & Type
6.1 Vaginitis Therapeutics Market Share by Region, 2017 & 2025
6.2 North America
6.2.1 North America vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.2.2 The U.S.
6.2.2.1 U.S vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.3.2 The U.K.
6.3.2.1 U.K. vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1亚洲Pacific vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1巴西阴道炎治疗市场,2014年- 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA vaginitis therapeutics market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa vaginitis therapeutics market, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 Symbiomix Therapeutics LLC.
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 Merck & Co., Inc.
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 Pfizer Inc.
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 Product Benchmarking
7.3.3.4 Strategic Initiatives
7.3.4 Novartis AG
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.5 Teva Pharmaceutical Industries Ltd.
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.6 Bayer AG
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.6.4 Strategic Initiatives
7.3.7 Janssen Pharmaceuticals Inc.
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.8 Lupin Pharmaceuticals Inc.
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 Lumavita AG.
7.3.9.1 Company Overview
7.3.9.2 Product Benchmarking
7.3.10 Mission Pharmacal Company.
7.3.10.1 Company Overview
7.3.10.2 Financial Performance
7.3.10.3 Product Benchmarking

List of Tables

TABLE 1 North America vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 2 North America vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 3 U.S. vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 4 U.S. vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 5 Canada vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 6 Canada vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 7 Europe vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 8 Europe vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 9 U.K. vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 10 U.K. vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 11 Germany vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 12 Germany vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 13 Asia Pacific vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 14 Asia Pacific vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 15 Japan vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 16 Japan vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 17 China vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 18 China vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 19 Latin America vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 20 Latin America vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 21 Brazil vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 22 Brazil vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 23 Mexico vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 24 Mexico vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 25 MEA vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 26 MEA vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)
TABLE 27 South Africa vaginitis therapeutics market, by product, 2014 - 2025 (USD Million)
TABLE 28 South Africa vaginitis therapeutics market, by type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Value chain based sizing & forecasting
FIG. 4 QFD modeling for market share assessment
FIG. 5 Market summary, 2017
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Market driver relevance analysis (Current & future impact)
FIG. 9 Market restrain relevance analysis (Current & future impact)
FIG. 10 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Vaginitis therapeutics market type outlook key takeaways
FIG. 13 Vaginitis therapeutics market: Product movement analysis
FIG. 14 Global anti-fungal market, 2014 - 2025 (USD Million)
FIG. 15 Global anti-bacterial market, 2014 - 2025 (USD Million)
FIG. 16 Global hormone market, 2014 - 2025 (USD Million)
FIG. 17 Vaginitis therapeutics market type outlook key takeaways
FIG. 18 Vaginitis therapeutics market: Type movement analysis
FIG. 19 Global Over the counter (OTC) market, 2014 - 2025 (USD Million)
FIG. 20 Global prescription (Rx) market, 2014 - 2025 (USD Million)
FIG. 21 Regional market place: Key takeaways
FIG. 22 Regional outlook, 2017 & 2025
FIG. 23 North America vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 24 U.S vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 25 Canada vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 26 Europe vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 27 U.K. vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 28 Germany vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 29 Asia Pacific vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 30 Japan vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 China vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 Latin America vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Brazil vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 Mexico vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 MEA vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 South Africa vaginitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 Strategy framework
FIG. 38 Participant categorization